Researchers at Stanford have developed a CRISPR-based system to degrade viral RNA, with potential applications as both an anti-viral therapeutic and a prophylactic treatment against influenza, SARS-CoV-2, and other viruses.
Stanford inventors have developed a method of using CRISPR/Cas9 or similar gene editing technologies to genetically edit an individual's own myeloid cells for specific gene targets, which are critical to wound repair, and applying these edited cells in a hydrogel to promote ra
Researchers in Prof. Michael Lin's laboratory have developed a viral-based cancer therapy platform that could be used for targeting treatment to cancer cells with aberrant signaling in EGFR or HER2 pathways.
Researchers in Prof. Stephen Quake's laboratory have developed a CRISPER-Cas-based targeted endonuclease system designed to treat latent viral infections by attacking the viral genome.
Researchers at Stanford have developed methods of using CRISPR/Cas9-mediated genome editing to treat patients with EGFR-mutant non-small-cell lung cancer (NSCLC). Approximately 85% of lung cancers are NSCLC.